Physician
Pain Management Centers of America, PSC
Pain Management Centers of America, PSC was paid $11.24M by Medicaid between Jan 2019 and Dec 2024, across 67 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 25% of everything it billed.
33Billing provider infoPAIN MANAGEMENT CENTERS OF AMERICA, PSC
EVANSVILLE, IN 47714
EVANSVILLE, IN 47714
33aNPI1992271811assigned 10/18/2018
33bProvider typePsychiatry Physician
28Total paid$11.24M
24GClaims358,715
24DCodes billed67
24AFirst – last monthJan 2019 – Dec 2024
Compared with peers
Next to other Psychiatry Physician providers in Indiana
Rank by total paid#1 of 68
Median peer was paid$115K
This provider vs. median98×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 59,146 | $1.53M | |
| 2020 | 67,104 | $1.90M | |
| 2021 | 65,528 | $2.14M | |
| 2022 | 66,332 | $2.08M | |
| 2023 | 61,372 | $2.04M | |
| 2024incomplete | 39,233 | $1.54M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 25% | 119,819 | 93,627 | $2.80M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 21% | 72,853 | 61,679 | $2.36M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 19% | 62,454 | 50,331 | $2.14M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 18% | 41,908 | 35,587 | $2.08M |
| 62323 | 2.9% | 5,225 | 4,260 | $320K | |
| 64483 | 1.8% | 2,740 | 2,288 | $199K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.5% | 2,462 | 1,994 | $167K |
| 62321 | 1.2% | 2,271 | 1,888 | $136K | |
| 99442 | <1% | 5,828 | 4,392 | $97K | |
| 64490 | <1% | 1,222 | 990 | $79K | |
| 62370 | <1% | 3,338 | 2,042 | $76K | |
| 64633 | <1% | 474 | 402 | $73K |
55 more codes
| 64493 | <1% | 1,076 | $60K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,529 | $58K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,479 | $58K |
| 64484 | <1% | 1,105 | $57K | |
| 27096 | <1% | 435 | $55K | |
| 62369 | <1% | 2,288 | $48K | |
| 64491 | <1% | 1,306 | $43K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 567 | $34K |
| 64494 | <1% | 1,102 | $32K | |
| 64420 | <1% | 1,285 | $28K | |
| 64421 | <1% | 2,049 | $28K | |
| 64634 | <1% | 560 | $26K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 461 | $24K |
| 64635 | <1% | 108 | $19K | |
| 76881 | <1% | 391 | $19K | |
| 95886 | <1% | 221 | $15K | |
| 95913 | <1% | 77 | $9K | |
| 77002 | <1% | 771 | $9K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 440 | $7K |
| 99205 | Prolong outpt/office vis | <1% | 81 | $7K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 2,140 | $7K |
| 64636 | <1% | 128 | $7K | |
| J3490 | Unclassified drugs | <1% | 2,290 | $7K |
| 95911 | <1% | 82 | $6K | |
| 20610 | <1% | 203 | $5K | |
| 00670 | <1% | 76 | $5K | |
| 99443 | <1% | 212 | $5K | |
| 20611 | <1% | 74 | $4K | |
| 76942 | <1% | 87 | $3K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 114 | $3K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 66 | $3K |
| 99406 | <1% | 788 | $2K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 310 | $2K |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 314 | $2K |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 255 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 255 | $2K |
| 20552 | <1% | 67 | $2K | |
| 99072 | <1% | 3,280 | $2K | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 147 | $2K |
| 99441 | <1% | 51 | $926.78 | |
| 01940 | <1% | 28 | $780.50 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,868 | $389.37 |
| 98967 | <1% | 170 | $340.77 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 462 | $183.27 |
| 77003 | <1% | 69 | $174.85 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 122 | $111.27 |
| 80305 | <1% | 158 | $69.88 | |
| 62368 | <1% | 15 | $40.46 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 19 | $2.02 |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 0% | 1,425 | $0.00 |
| G9562 | Patients who had a follow-up evaluation conducted at least every three months during opioid therapy | 0% | 1,204 | $0.00 |
| G9584 | Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy | 0% | 1,242 | $0.00 |
| 888888 | 0% | 77 | $0.00 | |
| A4220 | Refill kit for implantable infusion pump | 0% | 77 | $0.00 |
| G9578 | Documentation of signed opioid treatment agreement at least once during opioid therapy | 0% | 915 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSANAPATI, MAHENDRA (PRESIDENTR)
| Provider | Location | Paid |
|---|---|---|
| Advanced Pain Care Clinic PSC | Evansville, IN | $1.18M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.